These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 582985)

  • 1. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
    Walter-Sack I; Gröbner W; Zöllner N
    Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetic studies on plasma elimination half-life of oxipurinol (author's transl)].
    Lach HJ; Bader B; Schnitker J; Harries EH
    Arzneimittelforschung; 1982; 32(1):76-9. PubMed ID: 7199345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
    Fenner H; Schiemann O; Gikalov I
    Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
    Gikalov I; Radivojevich F; Schiemann O; Fenner H
    Arzneimittelforschung; 1986 Jun; 36(6):988-93. PubMed ID: 3741536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new and quick method for determination of allopurinol and oxipurinol in serum (author's transl)].
    Nitsche V; Mascher H
    Arzneimittelforschung; 1980; 30(11):1855-7. PubMed ID: 7192993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.
    Walter-Sack I; de Vries JX; Ernst B; Frei M; Kolb S; Kosmowski J; Priebe U; Schroder HE; Slotty C; Voss A; Weber A; Wegscheider K
    J Rheumatol; 1996 Mar; 23(3):498-501. PubMed ID: 8832991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
    Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
    Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of allopurinol in long-term treatments for optimal effect].
    Fenner H
    Fortschr Med; 1980 Mar; 98(10):(373-6). PubMed ID: 7372221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.
    Day RO; Miners J; Birkett DJ; Graham GG; Whitehead A
    Br J Clin Pharmacol; 1988 Oct; 26(4):429-34. PubMed ID: 3190993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.
    Walter-Sack I; de Vries JX; Kutschker C; Ittensohn A; Voss A
    Eur J Clin Pharmacol; 1995; 49(3):215-20. PubMed ID: 8665998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative study of the bioavailability and the pharmacodynamic effect of five allopurinol preparations (author's transl)].
    Jaeger H; Russmann D; Rasper J; Blome J
    Arzneimittelforschung; 1982; 32(4):438-43. PubMed ID: 6896646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].
    Schuster O; Haertel M; Hugemann B; Gikalov I; Schiemann O; Fenner H
    Arzneimittelforschung; 1985; 35(4):760-5. PubMed ID: 4015743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
    Breithaupt B; Tittel M
    Eur J Clin Pharmacol; 1982; 22(1):77-84. PubMed ID: 7094977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
    Saji M
    Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):640-50. PubMed ID: 9014485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
    Turnheim K; Krivanek P; Oberbauer R
    Br J Clin Pharmacol; 1999 Oct; 48(4):501-9. PubMed ID: 10583019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of allopurinol oral and rectal dosage forms.
    Chang SL; Kramer WG; Feldman S; Ballentine R; Frankel LS
    Am J Hosp Pharm; 1981 Mar; 38(3):365-8. PubMed ID: 7223751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
    Day RO; Miners JO; Birkett DJ; Whitehead A; Naidoo D; Hayes J; Savdie E
    Br J Clin Pharmacol; 1988 Oct; 26(4):423-8. PubMed ID: 3190992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.
    Peterson GM; Boyle RR; Francis HW; Oliver NW; Paterson J; von Witt RJ; Taylor GR
    Eur J Clin Pharmacol; 1990; 39(4):419-21. PubMed ID: 2076730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
    Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M; Sawchuk RJ
    Am J Vet Res; 1997 May; 58(5):504-10. PubMed ID: 9140559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma oxipurinol concentrations during allopurinol therapy.
    Emmerson BT; Gordon RB; Cross M; Thomson DB
    Br J Rheumatol; 1987 Dec; 26(6):445-9. PubMed ID: 3690140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.